34 terminated. 34 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 34 | Terminated 34 |
Follow Hyperlipidemias: new trials by email Literature Review of Hyperlipidemias trials Research Report on Hyperlipidemias
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Open Label Extension (OLE) Study to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230) Pelacarsen - Hyperlipoproteinemia (a) | Phase 3 | Terminated | Novartis Pharmaceuticals | 41 | 2023-09-29 | 2026-11-10 |
| Safety and Efficacy of Evolocumab in Addition to Optimal Stable Background Statin Therapy in Chinese Participants With Primary Hypercholesterolemia and Mixed Dyslipidemia evolocumab, placebo - Primary Hypercholesterolemia, Mixed Dyslipidemia | Phase 3 | Terminated | Amgen | 259 | 2019-05-09 | 2023-03-27 |
| A Study of Evacetrapib (LY2484595) in Combination With Atorvastatin in Japanese Participants With Primary Hypercholesterolemia Evacetrapib, Ezetimibe, Atorvastatin - Hypercholesterolemia | Phase 3 | Terminated | Eli Lilly and Company | 149 | 2015-01-01 | 2018-10-09 |
| A Study of Evacetrapib (LY2484595) in Japanese Participants With Primary Hypercholesterolemia Evacetrapib, Placebo - Hypercholesterolemia | Phase 3 | Terminated | Eli Lilly and Company | 54 | 2014-11-01 | 2018-10-09 |
| A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol Evacetrapib, Atorvastatin, Ezetimibe - Hyperlipidemia | Phase 3 | Terminated | Eli Lilly and Company | 366 | 2014-10-01 | 2019-10-08 |
| The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects bococizumab (PF-04950615), Placebo - Cardiovascular Disease | Phase 3 | Terminated | Pfizer | 10564 | 2013-10-29 | 2019-05-01 |
| The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects bococizumab (PF-04950615), Placebo - Cardiovascular Disease | Phase 3 | Terminated | Pfizer | 16784 | 2013-10-29 | 2018-07-11 |
| Efficacy and Tolerability of Anacetrapib Added to Ongoing Lipid-Lowering Therapy in Adult Participants With Homozygous Familial Hypercholesterolemia (HoFH) (MK-0859-042) Anacetrapib, Placebo - Hyperlipoproteinemia Type II, Homozygous Familial Hypercholesterolemia | Phase 3 | Terminated | Merck Sharp & Dohme LLC | 2 | 2013-06-01 | 2015-06-01 |
| Efficacy and Safety Study of Eprotirome in HeFH Patients Who Are on Optimal Standard of Care Placebo, Eprotirome - Heterozygous Familial Hypercholesterolaemia | Phase 3 | Terminated | Karo Bio AB | 236 | 2011-10-01 | 2012-09-03 |
| Efficacy and Safety of Extended-Release Niacin/ Laropiprant/Simvastatin Tablets in Participants With Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-143) ER niacin/laropiprant (ERN/LRPT), ER niacin/laropiprant/simvastatin (ERN/LRPT/SIM), Simvastatin (SIM) - Primary Hypercholesterolemia, Mixed Dyslipidemia | Phase 3 | Terminated | Merck Sharp & Dohme LLC | 1139 | 2011-05-01 | 2019-02-06 |
| Effects of a Supplement Derived From Palm Oil on Cholesterol Levels in the Blood Gamma Delta Tocotrienols - Low Dose, Gamma Delta Tocotrienols - High Dose, Sugar Pill - Hypercholesterolemia | Phase 3 | Terminated | University of California, Los Angeles | 13 | 2011-03-22 | 2019-02-12 |
| Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (MK-0524A-133) Extended-release niacin/laropiprant (ERN/LRPT), Placebo - Primary Hypercholesterolemia, Mixed Dyslipidemia | Phase 3 | Terminated | Merck Sharp & Dohme LLC | 1173 | 2011-03-01 | 2024-05-22 |
| A Study to Evaluate Efficacy and Safety of Extended-Release Niacin + Laropiprant + Simvastatin in Participants With Primary Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-118) Simvastatin, Extended Release (ER) niacin/laropiprant/simvastatin (N/LRPT/SIM), Extended Release (ER) niacin/laropiprant (N/LRPT) - Primary Hypercholesterolemia, Dyslipidemia | Phase 3 | Terminated | Merck Sharp & Dohme LLC | 977 | 2011-02-04 | 2018-08-16 |
| Ezetimibe in Patients Hypo-responsive to Statins Ezetimibe, Atorvastatin - High Cholesterol, Coronary Artery Disease | Phase 3 | Terminated | University of California, San Diego | 2 | 2009-09-01 | 2019-08-21 |
| Evaluation of Safety and Efficacy of AVE5530 as add-on to Ongoing High Doses of Statins in Patients With Primary Severe Hypercholesterolemia AVE5530, Placebo - Hypercholesterolemia | Phase 3 | Terminated | Sanofi | 643 | 2008-10-01 | 2016-05-16 |
| Evaluation of Efficacy and Safety of AVE5530 Co-administered With Atorvastatin in Primary Hypercholesterolemia AVE5530, atorvastatin, placebo - Hypercholesterolemia | Phase 3 | Terminated | Sanofi | 1736 | 2008-08-01 | 2016-05-16 |
| Evaluation of Safety and Efficacy of AVE5530 as add-on to Ongoing Statins in Patients With Primary Hypercholesterolemia 25 mg/day AVE5530, 50 mg/day AVE5530, placebo - Hypercholesterolemia | Phase 3 | Terminated | Sanofi | 1015 | 2008-07-01 | 2016-05-16 |
| Evaluation of Efficacy and Safety of AVE5530 in Patients With Primary Hypercholesterolemia AVE5530, Placebo - Hypercholesterolemia | Phase 3 | Terminated | Sanofi | 826 | 2008-07-01 | 2016-05-16 |
| Efficacy of Lapaquistat Acetate on Blood Cholesterol Levels in Treating Subjects With Hypercholesterolemia Lapaquistat acetate, Placebo - Hypercholesterolemia | Phase 3 | Terminated | Takeda | 657 | 2007-10-01 | 2012-05-24 |
| INdians Followed for INtensive Lipid Lowering Treatment and Its safetY ezetimibe, Comparator: Simvastatin 20, 40 and 80 mg, Comparator: Atorvastatin - Hypercholesterolemia | Phase 3 | Terminated | Sunnybrook Health Sciences Centre | 64 | 2007-08-01 | 2011-07-28 |
Showing 20 of 34. Sign in to see all of them.
Hypercholesterolemia (22) · Dyslipidemias (7) · Cardiovascular Diseases (4) · Hyperlipoproteinemia Type II (4) · Coronary Artery Disease (2) · Myocardial Infarction (2) · Stroke (2) · Atherosclerosis (1) · Diabetes Mellitus (1) · Diabetes Mellitus, Type 2 (1) · Homozygous Familial Hypercholesterolemia (1) · Hyperlipoproteinemia Type III (1) · Hyperlipoproteinemias (1) · Hypertriglyceridemia (1)
Lipid Metabolism Disorders (34) · Metabolic Diseases (34) · Nutritional and Metabolic Diseases (34) · Dyslipidemias (27) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (5) · Genetic Diseases, Inborn (5) · Hyperlipoproteinemias (5) · Metabolism, Inborn Errors (5) · Vascular Diseases (5) · Heart Diseases (4) · Lipid Metabolism, Inborn Errors (4) · Myocardial Ischemia (4) · Pathological Conditions, Signs and Symptoms (4) · Arterial Occlusive Diseases (3)
Atorvastatin (11) · Simvastatin (6) · Ezetimibe (5) · 1-((1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl)acetyl)piperidine-4-acetic acid (4) · MK-0524 (4) · torcetrapib (4) · evacetrapib (3) · Ezetimibe, Simvastatin Drug Combination (2) · Niacin (2) · Rosuvastatin Calcium (2) · bococizumab (2) · 3-((3,5-dibromo-4-(4-hydroxy-3-(1-methylethyl)phenoxy)phenyl)amino)-3-oxopropanoic acid (1) · Fenofibrate (1) · Fluvastatin (1) · Lovastatin (1)
Pfizer (6) · Merck Sharp & Dohme LLC (5) · Sanofi (4) · Takeda (4) · Eli Lilly and Company (3) · Organon and Co (2) · Amgen (1) · Drug Commission of the German Medical Association (1) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (1) · Karo Bio AB (1) · Novartis Pharmaceuticals (1) · Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (1) · Sunnybrook Health Sciences Centre (1) · University of California, Los Angeles (1) · University of California, San Diego (1)
United States (18) · Canada (9) · France (6) · Israel (6) · Netherlands (6) · Czechia (5) · Puerto Rico (5) · Russia (5) · Australia (4) · Belgium (4) · Germany (4) · Hungary (4) · Poland (4) · Slovakia (4) · South Africa (4)
David Heber, MD, PhD (1) · Davidson Michael, MD (1) · Heiner K. Berthold, MD, PhD (1) · John Kastelein, Professor (1) · Ori Ben-Yehuda, MD (1)
PMID 21518985, PMID 28304242, PMID 29685591, PMID 29716940, PMID 35277540, PMID 16705107, PMID 17407645, PMID 17630038, PMID 19029469, PMID 21613319, PMID 24731671, PMID 28412650, PMID 37565307
2005 (2), 2023 (1)